Shorts down from 230K to 154K

The number of shorted shares is now ( the 15th of Nov reading) lower than ever during the past year. It could be a small sign of something many of us are waiting for, the "transformative" year, 2022. Not much left of this 2022. However, there is nothing else to support any positive rumors IMO, but somebody could think that Kempler's talk at the annual meeting sounded positive: ".....we are gearing up for another exciting and productive year for Alterity, and we look forward to keeping you updated on our progress".

"Keeping you updated" should include PBT2, IMO. But it should include at least all ATH434 papers published but it is not the case. "ATH434 Rescues Pre-motor Hyposmia in a Mouse Model of Parkinsonism" published in September 2022 was never announced by the administration and I think it is a very important paper. Stamler was not included as an author, however.

Looks like there is nobody in the company who is concerned about us, the investors. We have lost during this past year more than half of the value of our investment. Hope that Kempler's words would become the main principle of the company, " ......keeping you updated on our progress". We have been waiting now 23 months for some news about PBT2. For us, as it is for the company, it is important to know at least something about PBT2 commercialization possibilities after these 23 months to value the company correctly. At the moment the valuation is based on "no news" and "we do not care to tell investors the real value of the company".